PrEP, or pre-exposure prophylaxis, was first approved by the FDA in 2012 to prevent people exposed to HIV from becoming ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

Five grantees, all in the South, will receive about $2 million each in federal funding for PrEP programs to prevent HIV.

Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...

Llenacapavir, a new HIV prevention injection, has been shown to have a 96% efficacy rate against the spread of the virus.

The trial pitted PrEP lenacapavir against standard-of-care once-daily Truvada (emtricitabine + tenofovir disoproxil fumarate). New safety data from the trial indicated that lenacapavir was ...